Theravance Biopharma (TBPH) Misses Q1 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. IVBIY

Go back to Theravance Biopharma (TBPH) Misses Q1 EPS by 23c

Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

May 5, 2022 4:05 PM EDT

Implied 35% share of YUPELRI® (revefenacin) net sales1: $15.3M Q1 2022 up 19% from Q1 2021TRELEGY Q1 2022 global net sales: $454M, up 33% from Q1 20212Results from a Phase 3 study of ampreloxetine showed a benefit in study patients with multiple system atrophy (MSA) Restructuring process completed in Q1 2022

DUBLIN, May 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2022.

... More